Clorox Co (NYSE:CLX) shares are rising higher on Wednesday. CNBC's “Halftime Report” highlighted the stock as a buying opportunity despite weakness across the consumer‑staples sector this month. Here’s what you additionally may want to know.

Analyst Commentary Sparks Interest

Jenny Harrington, CEO of Gilman Hill Asset Management, told CNBC she is buying Clorox now, arguing the stock looks undervalued relative to its long‑term history. Consumer staples have been the worst‑performing sector in the S&P 500 this month, but Harrington said the pullback is creating an attractive entry point.

CLX currently trades at 16x earnings, well below its historical range of 18x to 30x.

Dividend Strength Adds Support

Harrington also pointed to Clorox's income profile as a key reason she's stepping in. The stock carries a 4.9% dividend yield, and the company has paid that dividend for more than 50 years, raising it for 24 consecutive years.

She expects earnings to settle into a more consistent post‑pandemic trajectory, which she believes will support 6% to 8% earnings growth and 2% to 3% dividend growth going forward.

Recent Dip Tied To Input Costs

Part of the recent weakness in Clorox shares stems from rising input and distribution costs. A large portion of the company's cost structure is tied to petrochemicals, which have been affected by the ongoing U.S.–Iran conflict. Higher energy‑linked costs have pressured margins across the staples space.

Harrington argued that these pressures are temporary and that the long‑term fundamentals remain intact, seemingly helping lift Clorox today.

The Technical Analysis Of Clorox

Clorox is trading 8.7% below its 20-day SMA and 4.7% below its 100-day SMA, keeping the stock on the defensive across key trend gauges. Shares are down 26.28% over the past 12 months and are currently positioned closer to their 52-week lows than highs.

The RSI is at 28.85, which is oversold and lines up with the oversold trigger that hit on 2026-03-24. Meanwhile, MACD is at -3.5344 and remains below its signal line at -2.1592, a bearish configuration that suggests rallies may still face selling pressure.

The combination of oversold RSI (below 30) and bearish MACD suggests mixed momentum.

  • Key Resistance: $108.00
  • Key Support: $101.00

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $126.57. Recent analyst moves include:

  • Morgan Stanley: Equal-Weight (Raises Target to $136.00) (Feb. 5)
  • UBS: Neutral (Raises Target to $121.00) (Feb. 4)
  • Citigroup: Neutral (Raises Target to $115.00) (Feb. 4)

Benzinga Edge Rankings: The Benzinga Edge scorecard for Clorox highlighting its strengths and weaknesses compared to the broader market.

  • Momentum: Weak (Score: 18.46) — The stock is lagging, which fits with price sitting below key moving averages.
  • Quality: Strong (Score: 95.29) — The business scores well on quality factors, which can help support longer-term investor interest during drawdowns.
  • Value: Neutral (Score: 32.81) — Valuation looks more middle-of-the-road than deeply discounted, so the chart may need to improve to attract aggressive buyers.
  • Growth: Neutral (Score: 47.99) — Growth is not the main pillar here, so sentiment often hinges more on margins, pricing, and execution.

The Verdict: Clorox’s Benzinga Edge signal reveals a quality-led profile with weak momentum, suggesting the stock may need technical stabilization before the market rewards the fundamentals. If support near $101.00 holds, the oversold RSI could fuel a tradable rebound, but the bearish MACD argues for caution on chasing strength into resistance.

CLX Price Action: Clorox shares were up 1.38% at $104.49 at the time of publication on Wednesday, according to Benzinga Pro.

Image: Tamer A Soliman/Shutterstock